First Washington CORP Has $3.34 Million Position in Intrexon Corp (XON)

First Washington CORP increased its holdings in Intrexon Corp (NYSE:XON) by 47.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 289,990 shares of the biotechnology company’s stock after buying an additional 93,280 shares during the period. Intrexon accounts for 1.6% of First Washington CORP’s investment portfolio, making the stock its 29th biggest position. First Washington CORP owned approximately 0.23% of Intrexon worth $3,341,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Alliancebernstein L.P. boosted its holdings in Intrexon by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after buying an additional 200 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in Intrexon by 4.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock valued at $1,425,000 after purchasing an additional 2,468 shares during the period. Bank of New York Mellon Corp boosted its holdings in Intrexon by 1.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock valued at $4,512,000 after purchasing an additional 3,234 shares during the period. Advisor Group Inc. boosted its holdings in Intrexon by 61.5% in the 2nd quarter. Advisor Group Inc. now owns 8,797 shares of the biotechnology company’s stock valued at $212,000 after purchasing an additional 3,351 shares during the period. Finally, Teachers Advisors LLC boosted its holdings in Intrexon by 7.9% in the 2nd quarter. Teachers Advisors LLC now owns 57,840 shares of the biotechnology company’s stock valued at $1,393,000 after purchasing an additional 4,234 shares during the period. 75.10% of the stock is owned by institutional investors.

In other Intrexon news, CEO Randal J. Kirk bought 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 19th. The shares were bought at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 56.30% of the company’s stock.

Several research analysts have commented on the stock. Bank of America cut their price target on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. ValuEngine downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Stifel Nicolaus raised their price target on shares of Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a report on Friday, November 10th. Northland Securities reissued a “buy” rating and issued a $21.00 price target on shares of Intrexon in a report on Friday, November 10th. Finally, Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Intrexon currently has a consensus rating of “Hold” and an average price target of $38.50.

Intrexon Corp (NYSE:XON) opened at $12.37 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. The company has a market cap of $1,577.48, a price-to-earnings ratio of -11.04 and a beta of 1.40. Intrexon Corp has a fifty-two week low of $10.26 and a fifty-two week high of $26.99.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The firm had revenue of $46.02 million for the quarter, compared to analysts’ expectations of $55.17 million. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%. equities research analysts anticipate that Intrexon Corp will post -1.06 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/02/12/first-washington-corp-has-3-34-million-position-in-intrexon-corp-xon.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply